Brief: Newbury Pharmaceuticals Q2 EBITDA at SEK -4.15 Million
Apr 10 (Reuters) - Newbury Pharmaceuticals Q2 EBITDA SEK -4.147 million. * Q2 operating cash flow SEK -7.98 million * Q2 revenue SEK 3.135 million
Recent news on Newbury Pharmaceuticals AB
See all newsBrief: Newbury Secures Hospital Portfolio Rights In Iraq
Brief: Newbury Signs Licence And Supply Deal For Guanfacine
Brief: Newbury Pharmaceuticals Gets Approval for Tofacitinib Newbury
Brief: Newbury Pharmaceuticals Secures Generic Approval For Dalbavancin Newbury
Brief: Newbury Pharmaceuticals Reports Q3 EBITDA Of SEK -4 Mln